psoriatic%20arthritis
PSORIATIC ARTHRITIS
Psoriatic arthritis is a chronic inflammatory arthropathy associated with cutaneous psoriasis.
It is a progressive disease with asymmetric joint distribution pattern and rheumatoid factor is negative.
It can develop at any time including childhood but most often occurs between 30-50 years old.
Symptoms may range from mild to very severe.

Introduction

  • Psoriatic arthritis is a chronic inflammatory seronegative spondyloarthropathy associated w/ psoriasis
  • 6-42% of patients w/ psoriasis may develop psoriatic arthritis
  • Usually develops after an average of 12 yr of cutaneous manifestations
    • Dermatologists are encouraged to monitor for signs & symptoms of psoriatic arthritis every visit
    • All patients suspected of having psoriatic arthritis should be assessed by a rheumatologist so that an early diagnosis can be made & joint damage can be reduced 
  • Can develop at any time including childhood but most often occurs between 30-50 yr old
  • Affects men & women equally

Signs and Symptoms

  • Signs & symptoms include:
    • Peripheral joint pain, stiffness & swelling
    • Axial joint pain, stiffness & swelling
    • Tenderness of the joint & surrounding ligaments & tendons
    • Presence of skin & nail lesions
    • Enthesitis, tenosynovitis & dactylitis
    • Extra-articular manifestations (ie uveitis) 
  • Symptoms range from mild to very severe
    • Severity of the skin disease & the arthritis do not correlate w/ each other
    • Nail disease is commonly found in patients w/ psoriatic arthritis especially those w/ distal interphalangeal joint involvement
    • Psoriatic arthritis may start slowly w/ mild symptoms or may be preceded by a joint injury
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
DOWNLOAD
Editor's Recommendations
Most Read Articles
Elvira Manzano, 17 Oct 2017
Bisphosphonates have proven antifracture efficacy and remain to be the cornerstone of osteoporosis treatment. However, a drug holiday is of particular importance with bisphosphonates due to some signals with long-term use of the drug, including rare incidence of atypical femoral fracture (AFF) and osteonecrosis of the jaw (ONJ), says a leading endocrinologist at AFOS 2017.
Kavitha G. Shekar, 14 Jun 2016
The incidence of type 1 diabetes mellitus (T1D) was found to be higher in juvenile idiopathic arthritis patients (JIA) compared with the general population, said German researchers at the European League Against Rheumatism Annual Congress (EULAR 2016) held in London, UK.
Elaine Tan, 29 Jun 2017

Tofacitinib, a first-in-class Janus kinase (JAK) inhibitor, shows promise as an oral treatment with quick onset of action and sustained efficacy in patients with psoriatic arthritis (PsA) who do not respond adequately to conventional synthetic disease-modifying anti-rheumatic drugs (csDMARDs). 

Elvira Manzano, 13 Jun 2016
The oral Janus kinase (JAK) inhibitor tofacitinib may be a promising therapeutic option for patients with ankylosing spondylitis (AS), according to an expert who presented results from a phase II study that was touted as the first to demonstrate the efficacy of a JAK inhibitor in AS.